Summary
Mandatory screening performed by an experience ophthalmologist remains the most important pillar in the management of retinopathy of prematurity (ROP). The current gold standard for treatment of proliferative ROP is still panretinal laser photocoagulation, depending on severity, in combination with vitreoretinal surgery if necessary. The first case series of off-label intravitreal anti-VEGF treatment are encouraging. In addition to intravitreal anti-VEGF therapy, other treatment concepts such as supplementation with IGF-1 or omega-3 fatty acids also represent interesting pharmacological approaches to the management of ROP. However, larger controlled trials are required to validate the benefits and safety of these systemic treatment approaches.
Zusammenfassung
Ein verbindlich festgelegtes Screening durch erfahrene Ophthalmologen ist nach wie vor die wichtigste Säule im Management der Frühgeborenenretinopathie (ROP). Den derzeitigen Goldstandard zur Therapie der proliferativen ROP stellt nach wie vor die panretinale Laserkoagulation dar, je nach Schwere ggf. in Kombination mit vitreoretinaler Chirurgie. Die ersten Fallserien zur "off-label" durchgeführten intravitrealen Anti-VEGF-Therapie sind ermutigend. Neben der intravitrealen Anti-VEGF-Therapie stellen auch Behandlungskonzepte wie die Supplementation von IGF-1 oder ω3-Fettsäuren interessante pharmakologische Ansätze zur Behandlung der ROP dar. Allerdings müssen auch diese systemischen Therapieansätze ihren Nutzen und ihre Sicherheit erst in größeren kontrollierten Studien unter Beweis stellen.
Similar content being viewed by others
Literatur (Auswahl)
Atchaneeyasakul LO, Trinavarat A (2010) Choroidal ruptures after adjuvant intravitreal injection of bevacizumab for aggressive posterior retinopathy of prematurity. J Perinatol 30:497–499
Chung EJ, Kim JH, Ahn HS, Koh HJ (2007) Combination of laser photocoagulation and intravitreal bevacizumab (Avastin) for aggressive zone I retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol 245:1727–1730
Hellstrom A, Engstrom E, Hard AL et al (2003) Postnatal serum insulin-like growth factor I deficiency is associated with retinopathy of prematurity and other complications of premature birth. Pediatrics 112:1016–1020
Hoang QV, Kiernan DF, Chau FY et al (2010) Fluorescein angiography of recurrent retinopathy of prematurity after initial intravitreous bevacizumab treatment. Arch Ophthalmol 128:1080–1081
Honda S, Hirabayashi H, Tsukahara Y, Negi A (2008) Acute contraction of the proliferative membrane after an intravitreal injection of bevacizumab for advanced retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol 246:1061–1063
Jandeck C (2009) New therapeutic approaches in the treatment of retinopathy of prematurity. Klin Monatsbl Augenheilkd 226:914–920
Kusaka S, Shima C, Wada K et al (2008) Efficacy of intravitreal injection of bevacizumab for severe retinopathy of prematurity: a pilot study. Br J Ophthalmol 92:1450–1455
Kychenthal A, Dorta P (2010) Vitrectomy after intravitreal bevacizumab (Avastin) for retinal detachment in retinopathy of prematurity. Retina 30:S32–S36
Lalwani GA, Berrocal AM, Murray TG et al (2008) Off-label use of intravitreal bevacizumab (Avastin) for salvage treatment in progressive threshold retinopathy of prematurity. Retina 28:S13–S18
Lee JY, Chae JB, Yang SJ et al (2010) Effects of intravitreal bevacizumab and laser in retinopathy of prematurity therapy on the development of peripheral retinal vessels. Graefes Arch Clin Exp Ophthalmol 248:1257–1262
Lorenz B (2008) Current ophthalmic aspects of acute retinopathy of prematurity. Ophthalmologe 105:1092–1100
Mintz-Hittner HA, Kennedy KA, Chuang AZ (2011) Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med 364:603–615
Mintz-Hittner HA, Kuffel RR Jr (2008) Intravitreal injection of bevacizumab (avastin) for treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II. Retina 28:831–838
Nazari H, Modarres M, Parvaresh MM, Falavarjani KG (2010) Intravitreal bevacizumab in combination with laser therapy for the treatment of severe retinopathy of prematurity (ROP) associated with vitreous or retinal hemorrhage. Graefes Arch Clin Exp Ophthalmol 248:1713–1718
Nonobe NI, Kachi S, Kondo M et al (2009) Concentration of vascular endothelial growth factor in aqueous humor of eyes with advanced retinopathy of prematurity before and after intravitreal injection of bevacizumab. Retina 29:579–585
Pieh C, Agostini H, Buschbeck C et al (2008) VEGF-A, VEGFR-1, VEGFR-2 and Tie2 levels in plasma of premature infants: relationship to retinopathy of prematurity. Br J Ophthalmol 92:689–693
Pieh C, Kruger M, Lagreze WA et al (2010) Plasma sE-selectin in premature infants: a possible surrogate marker of retinopathy of prematurity. Invest Ophthalmol Vis Sci 51:3709–3713
Quiroz-Mercado H, Martinez-Castellanos MA, Hernandez-Rojas ML et al (2008) Antiangiogenic therapy with intravitreal bevacizumab for retinopathy of prematurity. Retina 28:S19–S25
Sapieha P, Stahl A, Chen J et al (2011) 5-lipoxygenase metabolite 4-HDHA is a mediator of the antiangiogenic effect of {omega}-3 polyunsaturated fatty acids. Sci Transl Med 3:69ra12
Sato T, Kusaka S, Shimojo H, Fujikado T (2009) Vitreous levels of erythropoietin and vascular endothelial growth factor in eyes with retinopathy of prematurity. Ophthalmology 116:1599–1603
Sato T, Shima C, Kusaka S (2011) Vitreous levels of angiopoietin-1 and angiopoietin-2 in eyes with retinopathy of prematurity. Am J Ophthalmol 151:353–357, e35
Shah PK, Morris RJ, Narendran V, Kalpana N (2011) Visual acuity and electroretinography findings 3 (1/2) years after the first intravitreal injection of bevacizumab (Avastin) in aggressive posterior retinopathy of prematurity. Indian J Ophthalmol 59:73–74
Smith LE (2008) Through the eyes of a child: understanding retinopathy through ROP the Friedenwald lecture. Invest Ophthalmol Vis Sci 49:5177–5182
Smith LE, Shen W, Perruzzi C et al (1999) Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor. Nat Med 5:1390–1395
Smith LE, Wesolowski E, McLellan A et al (1994) Oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci 35:101–111
Stahl A, Connor KM, Sapieha P et al (2010) The mouse retina as an angiogenesis model. Invest Ophthalmol Vis Sci 51:2813–2826
Stahl A, Sapieha P, Connor KM et al (2010) Short communication: PPAR gamma mediates a direct antiangiogenic effect of omega 3-PUFAs in proliferative retinopathy. Circ Res 107:495–500
Travassos A, Teixeira S, Ferreira P et al (2007) Intravitreal bevacizumab in aggressive posterior retinopathy of prematurity. Ophthalmic Surg Lasers Imaging 38:233–237
Wu WC, Yeh PT, Chen SN et al (2011) Effects and complications of bevacizumab use in patients with retinopathy of prematurity: a multicenter study in taiwan. Ophthalmology 118:176–183
Zepeda-Romero LC, Liera-Garcia JA, Gutierrez-Padilla JA et al (2010) Paradoxical vascular-fibrotic reaction after intravitreal bevacizumab for retinopathy of prematurity. Eye (Lond) 24:931–933
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Stahl, A., Agostini, H., Jandeck, C. et al. Pharmakologische Therapie der Frühgeborenenretinopathie. Spektrum Augenheilkd. 25, 319–330 (2011). https://doi.org/10.1007/s00717-011-0042-0
Issue Date:
DOI: https://doi.org/10.1007/s00717-011-0042-0